X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
YCANTH (formerly VP-10) is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of Common Warts.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
YCANTH (formerly VP-10) is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of Common Warts.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
TO-208 previously known as VP-102 is a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). It is being evaluated in phase 3 clinical trials for the treatment of Molluscum Contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: TO-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
The net proceeds will support the commercialization of Ycanth topical solution, a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin and the first and only FDA-approved treatment for molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 26, 2023
Details:
YCANTH™ (cantharidin) topical solution is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator, which is used for Molluscum Contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
VP-102 (cantharidin) activates or releases neutral ser- ine proteases that cause degeneration of the desmosmal plaque, leading to detachment of tonofilaments from des-mosomes. It is being developed for for the treatment of molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $32.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 21, 2023
Details:
VP-102, is a proprietary drug-device combination product that contains cantharidin (0.7% w/v) delivered via a singleuse applicator that allows for precise topical dosing and targeted administration. It is being developed for molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Torii Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
VP-102 (cantharidin), is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a singleuse applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration for treatment of molluscum contagiosum.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
Details:
Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Torii Pharmaceutical
Deal Size: $69.5 million Upfront Cash: $11.5 million
Deal Type: Licensing Agreement March 17, 2021
Details:
VP-102-(YCANTH) treated patients with lesions in the upper extremities, at baseline showed statistically significantly higher rates of complete clearance in those regions compared to vehicle beginning after the first treatment through the EOS visit.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
VP-102 is a first-in-class, proprietary drug-device combination for the treatment of molluscum, a viral skin disease affecting approximately six million people, primarily children, in the United States.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
VP-102 achieved positive results on both the primary endpoint of complete clearance of all treatable EGW at Day 84 and the secondary endpoint of the percentage reduction of EGW at Day 84.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Treatment with VP-102 demonstrated superior results compared to vehicle in the percentage of participants with complete clearance of molluscum lesions at the end of the trial.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Torii Pharmaceutical
Deal Size: $70.0 million Upfront Cash: $11.5 million
Deal Type: Agreement August 05, 2020
Details:
Company received a letter from the U.S.FDA as part of the FDA’s ongoing review of the its NDA for VP-102. The letter states that there are deficiencies that preclude discussion of labeling and post-marketing requirements/commitments.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: VP-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Pre-specified exploratory analysis showed VP-102 brought about a statistically significant percentage of patients with complete molluscum lesion clearance across all lesion count quartiles compared to vehicle.
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive
Lead Product(s): Cantharidin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ycanth
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
